Navigation Links
Takeda lanza nueva subsidiaria en Ecuador
Date:3/21/2013

Ecuador es un mercado dinámico y en crecimiento, impulsado por la inversión pública e industrias sólidas del petróleo y la minería. El PIB del país ascendió a más de $70 mil millones de dólares en 2012, mientras que las ventas farmacéuticas fueron de $1.27 mil millones de dólares y se espera que continúen creciendo en un 10% durante 2013*.  

En consonancia con la nueva estrategia de Takeda para los mercados emergentes, Takeda Ecuador está construyendo un portafolio de productos basado en las necesidades médicas de la población, con un enfoque en gastroenterología, cardiología, metabolismo, oncología y enfermedades respiratorias. La compañía se centrará inicialmente en Zurcal® (pantoprazol), Faktu® (policresuleno, clorhidrato de cincocaína) Alevian duo® (bromuro de pinaverio, dimeticona) y Tecta® (pantoprazol magnésico) y su producto de ginecología, Albothyl® (policresuleno), que Takeda repatrió después de la adquisición de Nycomed.

Takeda Ecuador planea aprovechar su plataforma de ventas con un flujo constante de lanzamientos de productos de su portafolio existente y los proyectos en desarrollo de I + D.

Carlos Haro ha sido nombrado Director General para Ecuador. Se une a la Compañía desde Sanofi, donde se desempeñó como Gerente General para Ecuador. Él dirigirá al equipo de puesta en marcha, mismo que irá creciendo constantemente a medida que la compañía amplíe su portafolio y entre en nuevas áreas terapéuticas.

"El lanzamiento de nuestra subsidiaria en Ecuador refuerza la posición de Takeda en América Latina y nos p
'/>"/>

SOURCE Takeda Pharmaceuticals International GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
2. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
3. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
4. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
5. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
6. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
7. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
8. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
9. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
10. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 According to Kalorama Information, electronic ... make Big Data in healthcare a reality, and this ... of the American Recovery and Reinvestment Act, the U.S. ... projects and penalties will start applying soon for use ... its complete study of the EMR industry, EMR ...
(Date:8/19/2014)... , Aug. 19, 2014  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... conferences: , Sanofi and Regeneron will host an IR ... on Tuesday, September 2, 2014 , Baird 2014 ... September 3, 2014 , Citi,s 9 th ... Thursday, September 4, 2014 , Morgan Stanley Global ...
(Date:8/19/2014)... PARK, Calif. , Aug. 19, 2014   DelMar ... a protocol amendment to allow for expanded dosing in its ... and Drug Administration (FDA) and that a new cohort of ... clinical trial sites in the United States ... million have been raised through warrant exercise in two separate ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... YORK, Nov. 17 Romeo and Juliette Laser ... hair removal center in New York City to own the ... leading developer and manufacturer of laser and light-based aesthetic treatment ... patented MultiPlex sequencing technology, is a highly versatile laser aesthetic ...
... , NEW YORK, Nov. 17 Engineer/pilot/attorney ... credit. They include technology that thwarts piracy in ... behind, devices to enhance airport security and even an ... interests that they have, indeed, found their match. ...
Cached Medicine Technology:Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2When Viruses (Including H1N1) and Bacteria are as Close as your Fingertips; VirWall's New Innovation Can Disarm Killer Keyboards 2
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... Aug. 19, 2014 (HealthDay News) -- Lupus and ... as headaches and seizures, which can delay a ... Treatments for rheumatic diseases can also cause ... Loyola University Medical Center in Maywood, Ill. ... the joints and soft tissues, such as lupus, ...
(Date:8/19/2014)... Just back from Glasgow where he helped distribute thousands ... Commonwealth Games (July 23 – August 6), Pete Dwan is ... And the need for his work cannot be overstated. , ... 59 consumed Class A drugs within the last year. And ... (NPS) drugs considered to be “legal highs” until June 2014, ...
(Date:8/19/2014)... Warfarin, the longtime standard treatment for atrial fibrillation, ... anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. ... these novel oral anticoagulants (NOACs) into clinical practice. ... new anticoagulant prescriptions yet this represents 98% of ... The American Journal of Medicine . , ...
(Date:8/19/2014)... City, Utah (PRWEB) August 19, 2014 ... Benefits Solution, published a new guide on compliance ... Zane Benefits, small businesses want to offer employee ... health insurance is unsustainable. Additionally, there are new ... portability, guaranteed-issue, and lower costs. , The ...
Breaking Medicine News(10 mins):Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3
... medications is associated with increased severity of erectile dysfunction, according ... British Journal of Urology International ., This study surveyed 37,712 ... taking various medications are likely to have more severe ED. ... multiethnic cohort of men ages 46 to 69 who are ...
... NJ . November 13, 2011. Kessler Foundation received a ... Geriatric Life Improvement. Anna Barrett, MD, director of Stroke ... to finding better ways to treat hidden disabilities that ... are pleased to receive this grant," said Rodger DeRose, ...
... By Serena Gordon HealthDay Reporter , MONDAY, Nov. ... warfarin need blood tests every four weeks to make sure ... suggests that some people could safely have those tests done ... isn,t an option for everyone on warfarin, just those who ...
... News) -- Drinking alcohol may be especially risky for young ... including having mothers, grandmothers or aunts with the disease, a ... Medicine in St. Louis examined data on more than 9,000 ... aged 9 to 15) through 2007. They focused on ...
... Indianapolis Wishard Health Services chief medical information officer, ... named one of America,s leading clinical informaticists by Modern ... Dr. Dexter is an associate professor of clinical medicine ... director of clinical applications at Wishard. "Dr. ...
... MONDAY, Nov. 14 (HealthDay News) -- Hearing loss affects ... far higher number than previously believed, researchers report. ... during National Health and Nutritional Examination Surveys (NHANES) from ... Organization,s definition of hearing loss (unable to hear sounds ...
Cached Medicine News:Health News:Erectile dysfunction increases with use of multiple medications 2Health News:Erectile dysfunction increases with use of multiple medications 3Health News:Kessler Foundation awarded stroke research grant by Wallerstein Foundation 2Health News:Warfarin May Need Less Monitoring for Some 2Health News:Warfarin May Need Less Monitoring for Some 3Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 2Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 3Health News:Indianapolis doc recognized as one of nation's top health info tech experts 2Health News:Indianapolis doc recognized as one of nation's top health info tech experts 3Health News:Hearing Loss Far More Common Than Expected 2
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
Medicine Products: